In this light, in 2016 the Cobas EGFR Mutation Test v2 (Roche) became the first liquid biopsy assay that obtained the approval of the FDA for the identification of NSCLC patients eligible for epidermal growth factor receptor (EGFR)-based targeted therapy [13]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.